Intravenous immunoglobulin in the treatment of neonatal sepsis: therapeutic strategies and laboratory studies.
IGIV appears to have a promising future in treating and perhaps preventing neonatal bacterial infections. However, all IGIV lots do not contain equal amounts of pathogen-specific IgG with functional opsonic activity. To ensure effective therapy it will be important to inform physicians that the IGIV lots available for use contain functional antibacterial antibody to the responsible pathogens. To optimize therapy IGIV may need to be given early in the infection and doses may need to be repeated if pathogen-specific antibody is rapidly depleted. Further, clinical studies will be necessary to determine if IGIV will be a valuable adjunct to antibiotic therapy in neonatal GBS infections.
D000818:Animals; D000833:Animals, Suckling; D000907:Antibodies, Bacterial / Q000032:analysis / Q000627:therapeutic use*; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000628:therapy*; D007275:Injections, Intravenous; D009895:Opsonin Proteins; D051381:Rats; D013292:Streptococcus agalactiae / Q000276:immunology*; D013997:Time Factors
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009895:Opsonin Proteins